Novo Nordisk

Novo Nordisk Pauses 3 Clinical Trials Testing Hemophilia Therapy
Novo Nordisk Pauses 3 Clinical Trials Testing Hemophilia Therapy
Xconomy
Novo Nordisk
clinical trials
concizumab
hemophilia
Flag link:
Insights into how Novo Nordisk's Saxenda cuts food cravings may inspire new obesity drugs
Insights into how Novo Nordisk's Saxenda cuts food cravings may inspire new obesity drugs
Fierce Biotech
Novo Nordisk
Saxenda
obesity
food cravings
Flag link:
Novo bids for recognition in the year of NASH
Novo bids for recognition in the year of NASH
EP Vantage
NASH
Novo Nordisk
Ozempic
Flag link:
Blockbusters in waiting: drug launches to watch in 2020
Blockbusters in waiting: drug launches to watch in 2020
Pharmaforum
drug launches
Biohaven
rimegepant
Novartis
ofatumumab
Celgene
ozanimod
Akebia Therapeutics
vadadustat
Biomarin
valrox
Gilead Sciences
filgotinib
Novo Nordisk
oral semaglutide
inclisiran
Immunomedics
sacituzumab govitecan
AstraZeneca
Enhertu
Bristol-Myers Squibb
liso-cel
Flag link:
How a cocktail of existing drugs could regenerate insulin-producing cells in diabetes
How a cocktail of existing drugs could regenerate insulin-producing cells in diabetes
Fierce Biotech
diabetes
insulin
Mt Sinai
Novo Nordisk
Ozempic
Rybelsus
Victoza
Eli Lilly
Trulicity
AstraZeneca
Bydureon
Flag link:
Lilly, Novo Nordisk Fight Insulin Biosimilars With Tweaks to FDA Draft Guidance
Lilly, Novo Nordisk Fight Insulin Biosimilars With Tweaks to FDA Draft Guidance
RAPS.org
diabetes
insulin
biosimilars
Eli Lilly
Novo Nordisk
FDA
competition
Flag link:
Biotech Q4 Earnings Synopsis: Major Restructuring and Overall Growth Are Themes
Biotech Q4 Earnings Synopsis: Major Restructuring and Overall Growth Are Themes
BioSpace
earnings
Bristol-Myers Squibb
AbbVie
Novo Nordisk
Merck
GSK
Seattle Genetics
Flag link:
Novo Nordisk investing $117.4M in manufacturing site in Denmark
Novo Nordisk investing $117.4M in manufacturing site in Denmark
Fierce Pharma
Novo Nordisk
insulin
diabetes
drug manufacturing
Flag link:
Ozempic acceleration buoys Novo Nordisk, and threatens Lilly
Ozempic acceleration buoys Novo Nordisk, and threatens Lilly
Pharmaforum
Novo Nordisk
earnings
Ozempic
Eli Lilly
diabetes
Flag link:
NICE shuns Novo Nordisk's obesity med Saxenda, citing CV questions
NICE shuns Novo Nordisk's obesity med Saxenda, citing CV questions
Fierce Pharma
Novo Nordisk
Saxenda
UK
NICE
Flag link:
Novo Nordisk’s quiet entry into the year of Alzheimer’s
Novo Nordisk’s quiet entry into the year of Alzheimer’s
EP Vantage
Novo Nordisk
Victoza
Alzheimer's disease
Flag link:
Novo Nordisk's diabetes pill Rybelsus to be covered by Express Scripts
Novo Nordisk's diabetes pill Rybelsus to be covered by Express Scripts
Reuters
Novo Nordisk
Rybelsus
Express Scripts
PBMs
Flag link:
Novo Nordisk's blockbuster Ozempic wins FDA label boost with CV indication
Novo Nordisk's blockbuster Ozempic wins FDA label boost with CV indication
Endpoints
Novo Nordisk
Ozempic
diabetes
cardiovascular events
FDA
Flag link:
FDA OKs Novo's Fiasp for diabetic children
FDA OKs Novo's Fiasp for diabetic children
Seeking Alpha
insulin
FDA
Novo Nordisk
Fiasp
pediatrics
diabetes
type 1 diabetes
Flag link:
Novo Nordisk Launches $99 Insulin Program
Novo Nordisk Launches $99 Insulin Program
BioSpace
Novo Nordisk
diabetes
insulin
drug pricing
Flag link:
Novo Nordisk joins with UVA in diabetes digital simulation project
Novo Nordisk joins with UVA in diabetes digital simulation project
Pharmaforum
Novo Nordisk
UVA
R&D
type 2 diabetes
Flag link:
ICER Warns of ‘Short-Term Budget Challenges’ with Novo’s Rybelsus
ICER Warns of ‘Short-Term Budget Challenges’ with Novo’s Rybelsus
Xtalks
Novo Nordisk
Rybelsus
oral semaglutide
diabetes
ICER
drug pricing
Flag link:
Novo Nordisk CEO Jørgensen aims to leverage diabetes know-how, deals into the new decade
Novo Nordisk CEO Jørgensen aims to leverage diabetes know-how, deals into the new decade
Fierce Pharma
Novo Nordisk
Lars Fruergaard Jorgensen
Pharma CEOs
diabetes
Flag link:
AZ, Merck and Novartis top Big Pharma's Q3 growth charts. Teva and Pfizer? Not so much
AZ, Merck and Novartis top Big Pharma's Q3 growth charts. Teva and Pfizer? Not so much
Fierce Pharma
earnings
Big Pharma
AstraZeneca
Merck
Celgene
Novartis
Novo Nordisk
Pfizer
Flag link:
Novo Ventures Sows $25M Into Accelerator to Break Into Illustrious Mass Bio Space
Novo Ventures Sows $25M Into Accelerator to Break Into Illustrious Mass Bio Space
Xconomy
Novo Ventures
Broad Institute
Harvard
biotech
accelerators
Massachusetts
Novo Nordisk
Flag link:

Pages